Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1642
This examiner grants 60% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17284525 | Method to Express, Purify, and Biotinylate Eukaryotic Cell-Derived Major Histocompatibility Complexes | Final Rejection | Texas Tech University System |
| 17918792 | SARS COV-2 VACCINES AND HIGH THROUGHPUT SCREENING ASSAYS BASED ON VESICULAR STOMATITIS VIRUS VECTORS | Final Rejection | Washington University |
| 17912726 | CHIMERIC ANTIGEN RECEPTOR SPECIFIC FOR HUMAN CD45RC AND USES THEREOF | Final Rejection | NANTES UNIVERSITE |
| 17294891 | Methods of Making Therapeutic T Lymphocytes | Final Rejection | NANTOMICS, LLC |
| 17950667 | CHIMERIC ANTIGEN RECEPTORS TARGETING CLAUDIN-3 AND METHODS FOR TREATING CANCER | Non-Final OA | GlaxoSmithKline Intellectual Property Development Limited |
| 18000380 | HYPERIMMUNE IGG AND/OR IGM COMPOSITIONS AND METHOD FOR PREPARING THEREOF AND METHOD FOR OBTAINING HYPERIMMUNE HUMAN PLASMA FROM A DONOR | Non-Final OA | GRIFOLS WORLDWIDE OPERATIONS LIMITED |
| 18063367 | THERAPEUTIC AND DIAGNOSTIC METHODS RELATING TO CANCER STEM CELLS | Non-Final OA | Children's Medical Center Corporation |
| 18052388 | MODIFIED J-CHAIN | Final Rejection | IGM Biosciences, Inc. |
| 18256278 | PEPTIDE COMPOSITIONS AND METHODS FOR ANTI-CD3 BINDING DOMAINS | Non-Final OA | Janux Therapeutics, Inc. |
| 17933295 | METHOD FOR TREATING A GD2 POSITIVE CANCER | Final Rejection | APEIRON BIOLOGICS GMBH |
| 18017173 | MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY | Non-Final OA | Dyne Therapeutics, Inc. |
| 17791697 | MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY | Final Rejection | Dyne Therapeutics, Inc. |
| 17058335 | MULTI-SPECIFIC BINDING PROTEINS AND IMPROVEMENTS THEREON | Final Rejection | Dragonfly Therapeutics, Inc. |
| 17927477 | Antigen Presenting Polypeptide Complexes and Methods of Use Thereof | Non-Final OA | Cue Biopharma, Inc. |
| 18066879 | METHODS OF TREATING CANCER USING ANTIBODIES AND MOLECULES THAT BIND TO BTN1A1 OR BTN1A1-LIGANDS | Non-Final OA | STCUBE & CO., INC. |
| 17999769 | CHIMERIC ANTIGEN RECEPTORS SPECIFIC FOR P95HER2 AND USES THEREOF | Non-Final OA | INSTITUCIO CATALANA DE RECERCA I ESTUDIS AVANCATS |
| 18046619 | DIAGNOSIS AND TREATMENT OF CANCER | Final Rejection | Rab Diagnostics AS |
| 17846846 | Tetravalent FZD and WNT Co-Receptor Binding Antibody Molecules and Uses Thereof | Non-Final OA | AntlerA Therapeutics Inc. |
| 17774111 | HUMANIZED ANTI-CA IX ANTIBODIES AND METHODS OF THEIR USE | Non-Final OA | MABPRO A.S. |
| 17702087 | METHODS FOR PREPARING AND ANALYZING BIOPSIES AND BIOLOGICAL SAMPLES | Non-Final OA | Nebulum Technologies Co., Ltd. |
| 17426141 | SURVIVAL-TARGETING CHIMERIC (SURTAC) MOLECULES | Non-Final OA | Entact Bio Limited |
| 17055561 | COMPOSITION OF BISPECIFIC ANTIBODIES AND METHOD OF USE THEREOF | Non-Final OA | ARBELE LIMITED |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy